The effect of immunosuppressive molecules on T-cell metabolic reprogramming

Biochimie

Volumn 127, Issue , 2016, Pages 23-36

  Fernández Ramos, Ana A ^a,b   Poindessous, Virginie ^a,b   Marchetti Laurent, Catherine ^a,b   Pallet, Nicolas ^a,b,c   Loriot, Marie Anne ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Aerobic glycolysis; Energetic metabolism; Immunosuppressive drugs; Metabolic reprogramming; Oxidative phosphorylation; T lymphocytes

Indexed keywords

ADENYLATE KINASE; CALCINEURIN INHIBITOR; CYCLOSPORIN A; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOSUPPRESSIVE AGENT; MAMMALIAN TARGET OF RAPAMYCIN; MERCAPTOPURINE; METHOTREXATE; MYC PROTEIN; MYCOPHENOLIC ACID; NUCLEOTIDE; PENTOSE PHOSPHATE; PURINE; RAPAMYCIN; TACROLIMUS;

CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL METABOLISM; CELL PROLIFERATION; GLYCOLYSIS; HUMAN; LYMPHOCYTE DIFFERENTIATION; NONHUMAN; NUCLEOTIDE METABOLISM; OXIDATIVE PHOSPHORYLATION; PENTOSE PHOSPHATE CYCLE; PURINE SYNTHESIS; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; ANIMAL; DRUG EFFECTS; IMMUNOLOGY; METABOLISM;

ANIMALS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; T-LYMPHOCYTES;

EID: 84975885917     PISSN: 03009084     EISSN: 61831638     Source Type: Journal    
DOI: 10.1016/j.biochi.2016.04.016     Document Type: Review

References (131)

1. [1] Pearce, E.L., Poffenberger, M.C., Chang, C.H., Jones, R.G., Fueling immunity: insights into metabolism and lymphocyte function. Science, 342(6155), 2013, 1242454.
2. [2] Palsson-McDermott, E.M., O'Neill, L.A., The Warburg effect then and now: from cancer to inflammatory diseases. BioEssays 35:11 (2013), 965–973.
3. [3] Vander-Heiden, M.G., Cantley, L., Thompson, C.B., Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324 (2009), 1029–1033.
4. [4] Pearce, E.L., Pearce, E.J., Metabolic pathways in immune cell activation and quiescence. Immunity 38:4 (2013), 633–643.
5. [5] Gatenby, R.A., Gillies, R.J., Why do cancers have high aerobic glycolysis?. Nat. Rev. Cancer 4 (2004), 891–899.
6. [6] Porporato, P.E., Dhup, S., Dadhich, R.K., Copetti, T., Sonvenaux, P., Anticancer targets in the glycolytic metabolism of tumors: a comprehensive review. Front. Pharmacol. 2:49 (2011), 1–18.
7. [7] Racker, E., History of the Pasteur effect and its pathobiology. Mol. Cell Biochem. 5 (1974), 17–23.
8. [8] MacIver, N.J., Michalek, R.D., Rathmell, J.C., Metabolic regulation of T lymphocytes. Annu. Rev. Immunol. 31 (2013), 259–283.
9. [9] Macintyre, A.N., Rathmell, J.C., Activated lymphocytes as a metabolic model for carcinogenesis. Cancer Metab. 1 (2013), 1–12.
10. [10] Warburg, O., On the origin of cancer cells. Science 123:3191 (1956), 309–314.
11. [11] Iurlaro, R., León-Annicchiarico, C.L., Muñoz-Pinedo, C., Regulation of cancer metabolism by oncogenes and tumor suppressors. Methods Enzymol. 542 (2014), 59–80.
12. [12] Galluzzi, L., Kepp, O., Heiden, M.G.V., Kroemer, G., Metabolic targets for cancer therapy. Nat. Rev. Drug Discov. 12 (2013), 829–946.
13. [13] Mason, E.F., Zhao, Y., Goraksha-Hicks, P., Coloff, J.L., Gannon, H., Jones, S.N., et al. Aerobic glycolysis suppresses p53 activity to provide selective protection from apoptosis upon loss of growth signals or inhibition of BCR-AbI. Cancer Res. 70:20 (2010), 8066–8076.
14. [14] Wang, R., Green, D.R., Metabolic reprogramming and metabolic dependency in T cells. Immunol. Rev. 249 (2012), 14–26.
15. [15] Yang, C., Ko, B., Hensley, C.T., Jiang, L., Wasti, A.T., Kim, J., et al. Glutamine oxidation maintains the TCA cycle and cell survival during impaired mitochondrial pyruvate transport. Mol. Cell. 56:3 (2014), 414–424.
16. [16] Amelio, I., Cutruzzolá, F., Antonov, A., Agostini, M., Melino, G., Serine and glycine metabolism in cancer. Trends Biochem. Sci. 39:4 (2014), 191–198.
17. [17] Locasale, J.W., Serine, glycine and one-carbon units: cancer metabolism in full circle. Nat. Rev. Cancer 13 (2013), 572–583.
18. [18] Buck, M.D., O'Sullivan, D., Pearce, E.L., T cell metabolism drives immunity. J. Exp. Med. 212:9 (2015), 1345–1360.
19. [19] Green, D.R., Galluzzi, L., Kroemer, G., Metabolic control of cell death. Science, 345(6203), 2014, 1250256.
20. [20] Parkin, J., Cohen, B., An overview of the immune system. Lancet 357 (2001), 1777–1789.
21. [21] Pearce, E.L., Metabolism in T cell activation and differentiation. Curr. Opin. Immunol. 22:3 (2010), 314–320.
22. [22] O'Sullivan, D., Pearce, E.L., Targeting T cell metabolism for therapy. Trends Immunol. 36 (2015), 71–80.
23. [23] Pollizzi, K.N., Powell, J.D., Integrating canonical and metabolic signalling programmes in the regulation of T cell responses. Nat. Rev. Immunol. 14:7 (2014), 435–446.
24. [24] Parijs, L.V., Abbas, A.K., Homeostasis and self-tolerance in the immune system: turning lymphocytes off. Science 280 (1998), 243–248.
25. [25] O'Sullivan, D., van der Windt, G.J., Huang, S.C., Curtis, J.D., Chang, C.H., Buck, M.D., et al. Memory CD8(+) T cells use cell-intrinsic lipolysis to support the metabolic programming necessary for development. Immunity 41:1 (2014), 75–88.
26. [26] Cao, Y., Rathmell, J.C., Macintyre, A.N., Metabolic reprogramming towards aerobic glycolysis correlates with greater proliferative ability and resistance to metabolic inhibition in CD8 versus CD4 T cells. PLoS One, 9(8), 2014, e104104.
27. [27] Nizet, V., Johnson, R.S., Interdependence of hypoxic and innate immune responses. Nat. Rev. Immunol. 9 (2009), 609–617.
28. [28] Quemeneur, L., Gerland, L.M., Flacher, M., Ffrench, M., Revillard, J.P., Genestier, L., Differential control of cell cycle, proliferation, and survival of primary T lymphocytes by purine and pyrimidine nucleotides. J. Immunol. 170:10 (2003), 4986–4995.
29. [29] Chan, C.Y., Zhao, H., Pugh, R.J., et al. Purinosome formation as a function of the cell cycle. PNAS 112:5 (2015), 1368–1373.
30. [30] Moffatt, B.A., Ashihara, H., Purine and pyrimidine nucleotide synthesis and metabolism. Arab. Book, 1, 2002, e0018. doi: 10.1199/tab.0018.
31. [31] Jiang, P., Du, W., Wu, M., Regulation of the pentose phosphate pathway in cancer. Protein Cell. 5:8 (2014), 592–602.
32. [32] Tong, X., Zhao, F., Thompson, C.B., The molecular determinants of de novo nucleotide biosynthesis in cancer cells. Curr. Opin. Genet. Dev. 19:1 (2009), 32–37.
33. [33] Phan, L.M., Yeung, S.C.J., Lee, M.H., Cancer metabolic reprogramming: importance, main features, and potentials for precise targeted anti-cancer therapies. Cancer Biol. Med. 11 (2014), 1–19.
34. [34] Wang, R., Green, D.R., Metabolic checkpoints in activated T cells. Nat. Immunol. 13:10 (2012), 907–915.
35. [35] Kondo, M., Yamaoka, T., Honda, S., Miwa, Y., Katashima, R., Moritani, M., et al. The rate of cell growth is regulated by purine biosynthesis via ATP production and G1 to S phase transition. J. Biochem. 128 (2000), 57–64.
36. [36] Stryer, L., Berg, J.M., Tymoczko, J.L., Nucleotide Biosynthesis. Freeman, W., (eds.) Biochemistry, sixth ed., 2007 New York.
37. [37] Allison, A.C., Eugui, E.M., Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 47 (2000), 85–118.
38. [38] Allison, A.C., Eugui, E.M., The design and development of an immunosuppressive drug, mycophenolate mofetil. Springer Semin. Immunopathol. 14 (1993), 353–380.
39. [39] Laliberté, J., Yee, A., Xiong, Y., Mitchell, B.S., Effects of guanine nucleotide depletion on cell cycle progression in human T lymphocytes. Blood 91:8 (1998), 2896–2904.
40. [40] Quemeneur, L., Flacher, M., Gerland, L.M., Ffrench, M., Revillard, J.P., Bonnefoy-Berard, N., Mycophenolic acid inhibits IL-2-Dependent T cell proliferation, But Not IL-2-dependent survival and sensitization to apoptosis. J. Immunol. 169:5 (2002), 2747–2755.
41. [41] Taylor, A.L., Watson, C.J., Bradley, J.A., Immunosuppressive agents in solid organ transplantation: Mechanisms of action and therapeutic efficacy. Crit. Rev. Oncol. Hematol. 56:1 (2005), 23–46.
42. [42] Gwinn, D.M., Shackelford, D.B., Egan, D.F., Mihaylova, M.M., Mery, A., Vasquez, D.S., et al. AMPK phosphorylation of Raptor mediates metabolic checkpoint. Mol. Cell. 30 (2008), 214–226.
43. [43] Faubert, B., Boily, G., Izreig, S., Griss, T., Samborska, B., Dong, Z., et al. AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo. Cell Metab. 17 (2013), 113–124.
44. [44] Inoki, K., Kim, J., Guan, K.L., AMPK and mTOR in cellular energy homeostasis and drug targets. Annu. Rev. Pharmacol. Toxicol. 52 (2012), 381–400.
45. [45] Blagih, J., Coulombe, F., Vincent, E.E., Dupuy, F., Galicia-Vazquez, G., Yurchenko, E., et al. The energy sensor AMPK regulates T cell metabolic adaptation and effector responses in vivo. Immunity 42:1 (2015), 41–54.
46. [46] Viollet, B., Guigas, B., Garcia, N.S., Leclerc, J., Foretz, M., Andreelli, F., Cellular and molecular mechanisms of metformin: an overview. Clin. Sci. (Lond) 122:6 (2012), 253–270.
47. [47] Salani, B., Rio, A.D., Marini, C., Sambuceti, G., Cordera, R., Maggi, D., Metformin, cancer and glucose metabolism. Endocr. Relat. Cancer 21 (2014), R461–R471.
48. [48] Marini, C., Salani, B., Massollo, M., Amaro, A., Esposito, A.I., Orengo, A.M., et al. Direct inhibition of hexokinase activity by metformin at least partially impairs glucose metabolism and tumor growth in experimental breast cancer. Cell Cycle 12:22 (2013), 3490–3499.
49. [49] Sahra, I.B., Marchand-Brustel, Y.L., Tanti, J.-F., Bost, F., Metformin in cancer therapy: a new perspective for an old antidiabetic drug?. Mol. Cancer Ther. 9:5 (2010), 1092–1099.
50. [50] Waickman, A.T., Powell, J.D., mTOR, metabolism, and the regulation of T-cell differentiation and function. Immunol. Rev. 249 (2012), 43–58.
51. [51] Chi, H., Regulation and function of mTOR signalling in T cell fate decisions. Nat. Rev. Immunol. 12:5 (2012), 325–338.
52. [52] Wouters, B.G., Koritzinsky, M., Hypoxia signaling through mTOR and the unfolded protein response in cancer. Nat. Rev. Cancer 8 (2008), 851–864.
53. [53] Maciolek, J.A., Pasternak, J.A., Wilson, H.L., Metabolism of activated T lymphocytes. Curr. Opin. Immunol. 27 (2014), 60–74.
54. [54] Roberts, D.J., Tan-Sah, V.P., Ding, E.Y., Smith, J.M., Miyamoto, S., Hexokinase-II positively regulates glucose starvation-induced autophagy through TORC1 inhibition. Mol. Cell. 53 (2014), 521–533.
55. [55] Jiang, B.-H., Liu, L.-Z., Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment. Drug Resist. Uptdate 11 (2008), 63–76.
56. [56] Zhdanov, A.V., Waters, A.H., Golubeva, A.V., Papkovsky, D.B., Differential contribution of key metabolic substrates and cellular oxygen in HIF signalling. Exp. Cell Res. 330:1 (2015), 13–28.
57. [57] Selak, M.A., Armour, S.M., MacKenzie, E.D., Boulahbel, H., Watson, D.G., Mansfield, K.D., et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-1a prolyl hydroxylase. Cancer Cell 7 (2005), 77–85.
58. [58] Eltzschig, H.K., Carmeliet, P., Hypoxia and inflammation. NEJM 364 (2011), 656–665.
59. [59] Tannahill, G., Curtis, A., Adamik, J., Palsson-McDermott, E., McGettrick, A., Goel, G., et al. Succinate is an inflammatory signal that induces IL-1b through HIF-1a. Nature 496 (2013), 238–242.
60. [60] Palsson-McDermott, E.M., Curtis, A.M., Goel, G., Lauterbach, M.A., Sheedy, F.J., Gleeson, L.E., et al. Pyruvate kinase M2 regulates Hif-1a activity and IL-1B induction and is a critical determinant of the Warburg effect in LPS-activated macrophages. Cell Metab. 21 (2015), 65–80.
61. [61] Yang, Z., Matteson, E.L., Goronzy, J.J., Weyand, C.M., T-cell metabolism in autoimmune disease. Arthritis Res. Ther., 17(1), 2015, 29.
62. [62] Wang, R., Dillon, C.P., Shi, L.Z., Milasta, S., Carter, R., Finkelstein, D., et al. The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. Immunity 35:6 (2011), 871–882.
63. + T cells. Nat. Immunol. 15:9 (2014), 828–829.
64. [64] Macintyre, A.N., Gerriets, V.A., Nichols, A.G., Michalek, R.D., Rudolph, M.C., Deoliveira, D., et al. The glucose transporter Glut1 is selectively essential for CD4 T cell activation and effector function. Cell Metab. 20:1 (2014), 61–72.
65. [65] Sinclair, L.V., Rolf, J., Emslie, E., Shi, Y.B., Taylor, P.M., Cantrell, D.A., Control of amino-acid transport by antigen receptors coordinates the metabolic reprogramming essential for T cell differentiation. Nat. Immunol. 14:5 (2013), 500–508.
66. + T cell differentiation. J. Clin. Investig., 125(5), 2015, 2090–2108.
67. [67] Yang, K., Shrestha, S., Zeng, H., Karmaus, P.W., Neale, G., Vogel, P., et al. T cell exit from quiescence and differentiation into Th2 cells depend on Raptor-mTORC1-mediated metabolic reprogramming. Immunity 39:6 (2013), 1043–1056.
68. [68] Dang, E.V., Barbi, J., Yang, H.Y., Jinasena, D., Yu, H., Zheng, Y., et al. Control of TH17/Treg balance by hypoxia-inducible factor 1. Cell Metab. 146 (2011), 772–784.
69. [69] Shi, L.Z., Wang, R., Huang, G., Vogel, P., Neale, G., Green, D.R., et al. HIF1a-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of Th17 and Treg cells. JEM 208 (2011), 1367–1376.
70. [70] Clambey, E.T., McNamee, E.N., Westrich, J.A., Glover, L.E., Campbell, E.L., Jedlicka, P., et al. Hypoxia-inducible factor-1 alpha-dependent induction of FoxP3 drives regulatory T-cell abundance and function during inflammatory hpoxia of the mucosa. PNAS 17 (2012), 2784–2793.
71. [71] Patsoukis, N., Bardhan, K., Chatterjee, P., Sari, D., Liu, B., Bell, L.N., et al. PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. Nat. Commun., 6, 2015, 6692.
72. [72] Araki, K., Turner, A.P., Shaffer, V.O., Gangappa, S., Keller, S.A., Bachmann, M.F., et al. mTOR regulates memory CD8 T-cell differentiation. Nature 460:7251 (2009), 108–112.
73. [73] Wiseman, A.C., Immunosuppressive medications. CJASN, 11(2), 2016, 332-343.
74. [74] Halloran, P.F., Immunosuppressive drugs fot kidney transplantation. NEJM 351:26 (2004), 2715–2729.
75. [75] Zeiser, R., Negrin, R.S., Interleukin-2 receptor downstream events in regulatory T cells: implications for the choice of immunosuppressive drug therapy. Cell Cycle 7:4 (2008), 458–462.
76. [76] Allison, A.C., Immunosuppressive drugs: the first 50 years and a glance forward. Immunopharmacology 47 (2000), 63–83.
77. [77] Baselga, J., Campone, M., Piccart, M., Burris, H.A., Rugo, H.S., Sahmoud, T., et al. Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer. NEJM 366:6 (2012), 520–529.
78. [78] Perl, A., Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases. Nat. Rev. Rheumatol. 12 (2016), 169–182.
79. [79] Owonikoko, T.K., Ramalingam, S.S., Miller, D.L., A translational, pharmacodynamic, and pharmacokinetic phase IB clinical study of Everolimus in resectable non-small cell lung cancer. Clin. Cancer Res. 21 (2015), 1859–1868.
80. [80] Patel, J.K., Kobashigawa, J.A., Everolimus: an immunosuppressive agent in transplantation. Expert Opin. Pharmacother. 7:10 (2006), 1347–1355.
81. [81] Powell, J.D., Delgoffe, G.M., The mammalian target of rapamycin: linking T cell differentiation, function, and metabolism. Immun. Rev. 33 (2010), 301–311.
82. [82] Kato, H., Perl, A., Mechanistic target of rapamycin complex 1 expands Th17 and IL4+ CD4-CD8- double-negative T cells and contracts regulatory T cells in systemic lupus erythematosus. J. Immunol. 192 (2014), 4134–4144.
83. [83] Li, Y., Shen, C., Zhu, B., Shi, F., Eisen, H.N., Chen, J., Persistent antigen and prolonged AKT-mTORC1 activation underlie memory CD8 T cell impairment in the absence of CD4 T cells. J. Immunol. 195 (2015), 1591–1598.
84. [84] Shan, J., Feng, L., Li, Y., Sun, G., Chen, X., Chen, P., The effects of rapamycin on regulatory T cells: its potential time-dependent role in inducing transplant tolerance. Immunol. Lett. 162 (2014), 74–86.
85. [85] Radu, R.G., Fujimoto, S., Mukai, E., Takehiro, M., Shimono, D., Nabe, K., et al. Tacrolimus suppresses glucose-induced release from pancreatic islets by reducing glucokinase activity. Am. J. Physiol. Endocrinol. Metab. 288 (2004), E365–E371.
86. [86] Hartono, C., Muthukumar, T., Suthanthiran, M., Immunosuppressive drug therapy. Cold Spring Harb. Perspect. Med. 3 (2013), 1–15.
87. [87] Barbarino, J.M., Staatz, C.E., Venkataramanan, R., Klein, T.E., Altman, R.B., PharmGKB summary: cyclosporine and tacrolimus pathways. Pharmacogenet. Genomics 23:10 (2013), 563–585.
88. [88] Pereira, M.J., Palming, J., Rizell, M., Aureliano, M., Carvalho, E., Svensson, M.K., et al. Cyclosporine A and Tacrolimus reduce the amount of GLUT4 at the cell surface in human adipocytes: increased endocytosis as a potential mechanism for the diabetogenic effects of immunosuppressive agents. J. Clin. Endocrinol. Metab. 99:10 (2014), E1885–E1894.
89. [89] Assmann, T., Homey, B., Ruzicka, T., Applications of tacrolimus for the treatment of skin disorders. Immunopharmacology 47 (2000), 203–213.
90. [90] Kapp, A., Allen, B., Reitamo, S., Atopic dermatitis management with tacrolimus ointment (Protopic). Dermatol. Treat. 14:Suppl 1 (2003), 5–16.
91. [91] McCarey, D., Capell, H., Madhok, R., Tacrolimus therapy in rheumatoid arthritis. Rheumatol. Oxf. 43:8 (2004), 946–948.
92. [92] Lee, S., Tan, A., Giam, Y., Cyclosporin in the treatment of severe atopic dermatitis: a retrospective study. Ann. Acad. Med. Singap. 33:3 (2004), 311–313.
93. [93] Wells, G., Tugwell, P., Cyclosporin A in rheumatoid arthritis: overview of efficacy. Br. J. Rheumatol. 32:Suppl 1 (1993), 51–56.
94. [94] Walczak-Drzewiecka, A., Ratajewski, M., Wagner, W., Dastych, J., HIF-1A is up-regulated in activated mast cells by a process that involves calcineurin and NFAT. J. Immunol. 181 (2008), 1665–1672.
95. [95] Liu, Y.V., Hubbi, M.E., Pan, F., McDonald, K.R., Mansharamani, M., Cole, R.N., et al. Calcineurin promotes hypoxia-inducible factor 1a expression by dephosphorylating RACK1 and blocking RACK1 dimerization. J. Biol. Chem. 282:51 (2007), 37064–37073.
96. [96] Singh, G., Singh, S.K., König, A., Reutlinger, K., Nye, M.D., Adhikary, T., et al. Sequential activation of NFAT and c-myc transcription factors mediates the TGF-B switch from a suppressor to a promoter of cancer cell proliferation. J. Biol. Chem. 285:35 (2010), 27241–27250.
97. [97] Buchholz, M., Schatz, A., Wagner, M., Michl, P., Linhart, T., Adler, G., et al. Overexpression of c-myc in pancreatic cancer caused by ectopic activation of NFATc1 and the Ca+2/calcineurin signaling pathway. EMBO J. 25 (2006), 3714–3724.
98. [98] Wang, S., Kang, X., Cao, S., Cheng, H., Wang, D., Geng, J., Calcineurin/NFATc1 pathway contributes to cell proliferation in hepatocellular carcinoma. Dig. Dis. Sci. 57 (2012), 3184–3188.
99. [99] Mognol, G.P., PSd, Araujo-Souza, Robbs, B.K., Teixera, L.K., Viola, J.P., Transcriptional regulation of the c-myc promoter NFAT1 involvers negative and positive NFAT-responsive elements. Cell Cycle 11:5 (2012), 1014–1028.
100. [100] Basu, A., Banerjee, P., Contreras, A.G., Flynn, E., Pal, S., Calcineurin inhibitor-induced and ras-mediated overexpression of VEGF in renal cancer cells involves mTOR through the regulation of PRAS40. PLoS One, 6(8), 2011, e23919.
101. [101] Basu, A., Banerjee, P., Pal, S., Critical role of mTOR in calcineurin inhibitor-induced renal cancer progression. Cell Cycle 11:4 (2012), 633–634.
102. [102] Illsinger, S., Göken, C., Brockmann, M., Thiemann, I., Bednarczyk, J., Schmidt, K.-H., et al. Effect of tacrolimus on energy metabolism in human umbilical endothelial cells. Ann. Transpl. 16:2 (2011), 68–75.
103. [103] Illsinger, S., Janzen, N., Lücke, T., Bednarczyk, J., Schmidt, K., Hoy, L., et al. Cyclosporine A: impact on mitochondrial function in endothelial cells. Clin. Transpl. 25 (2011), 584–593.
104. [104] Fuhrmann, A., Lopes, P., Sereno, J., Pedro, J., Espinoza, D., Pereira, M., et al. Molecular mechanisms underlying the effects of cyclosporin A and sirolimus on glucose and lipid metabolism in liver, skeletal muscle and adipose tissue in an in vivo rat model. Biochem. Pharmacol. 88 (2014), 216–228.
105. [105] Elion, G.B., The Purine Path to Chempotherapy. 1989, 41–47.
106. [106] Chouchana, L., Narjoz, C., Beaune, P., Loriot, M., Roblin, X., Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease. Aliment. Pharmacol. Ther. 35 (2012), 15–36.
107. [107] Weigel, G., Griesmacher, A., DeAbreu, R.A., Wolner, E., Mueller, M.M., Azathioprine and 6-mercaptopurine alter the nucleotide balance in endothelial cells. Thromb. Res. 94 (1999), 87–94.
108. [108] Thomas, C.W., Myhre, G.M., Tschumper, R., Sreekumar, R., Jelinek, D., McKean, D.J., et al. Selective inhibition of inflammatory gene expression in activated T lymphocytes: a mechanism of immune suppression by thiopurines. JPET 312:2 (2005), 537–545.
109. [109] Ordentlich, P., Yan, Y., Zhou, S., Heyman, R.A., Identification of the antineoplastic agent 6-mercaptopurine as an activator of the orphan nuclear hormone receptor Nurr1. J. Biol. Chem. 278:27 (2003), 24791–24799.
110. [110] Karran, P., Attard, N., Thiopurines in current medical practice: molecular mechanisms and contributions to therapy-related cancer. Nat. Rev. Cancer 8 (2008), 24–36.
111. [111] Stet, E.H., Abreu, R.A.D., Janssen, Y.P., Bökkerink, P.P., Trijbels, F.J., A biochemical basis for synergism of 6-mercaptopurine and mycophenolic acid in Molt F4, a human malignant T-lymphoblastic cell line. Biochem. Biophys. 1180 (1993), 277–282.
112. [112] Sugiyama, K., Satoh, H., Saito, K., Takahashi, K., Saito, N., Hirano, T., Immunosuppressive efficacy of mycophenolate mofetil when compared with azathioprine and mizoribine against peripheral lymphocytes from renal transplant recipients. Transpl. Int. 18:5 (2005), 590–595.
113. [113] Dayton, J.S., Turka, L.A., Thompson, C.B., Mitchell, B.S., Comparison of the effects of mizoribine with those of azathioprine, 6-mercaptopurine, and mycophenolic acid on T lymphocyte proliferation and purine ribonucleotide metabolism. Mol. Pharmacol. 41:4 (1992), 671–676.
114. [114] Yoo, Y., Na, T., Yang, W., Kim, H., Lee, I., Kong, G., et al. 6-mercaptopurine, an activator of Nur77, enhances transcriptional activity of HIF-1a resulting in new vessel formation. Oncogene 26 (2007), 3823–3834.
115. [115] Maripuri, S., Kasiske, B.L., The role of mycophenolate mofetil in kidney transplantation revisited. Transpl. Rev. 28:1 (2014), 26–31.
116. [116] Appel, A.S., Appel, G.B., An update on the use of mycophenolate mofetil in lupus nephritis and other primary glomerular diseases. Nat. Rev. Nephrol. 5 (2009), 132–142.
117. [117] Fassbinder, T., Saunders, U., Mickholz, E., Jung, E., Becker, H., Schlüter, B., et al. Differential effects of cyclophosphamide and mycophenolate mofetil on cellular and serological parameters in patients with systemic lupus erythematosus. Arthritis Res. Ther., 17(92), 2015.
118. [118] Domhan, S., Muschal, S., Schwager, C., Morath, C., Wirkner, U., Ansorge, W., et al. Molecular mechanisms of the antiangiogenic and antitumor effects of mycophenolic acid. Mol. Cancer Ther. 7:6 (2008), 1656–1667.
119. [119] Dun, B., Sharma, A., Xu, H., Liu, H., Bai, S., Zeng, L., et al. Transcriptomic changes induced by mycophenolic acid in gastric cancer cells. Am. J. Transl. Res. 6:1 (2014), 28–42.
120. [120] He, X., Smeets, R., Koenen, H., Vink, P., Wagenaars, J., Boots, A., et al. Mycophenolic acid-mediated suppression of human CD4+ T cells: more than mere guanine nucleotide deprivation. Am. J. Transpl. 11 (2011), 439–449.
121. [121] Dun, B., Xu, H., Sharma, A., Liu, H., Yu, H., Yi, B., et al. Delineation of biological and molecular mechanisms underlying the diverse anticancer activities of mycophenolic acid. Int. J. Clin. Exp. Pathol. 6:12 (2013), 2880–2886.
122. [122] Robien, K., Schubert, M., Yasui, Y., Martin, P., Storb, R., Potter, J., et al. Folic acid supplementation during methotrexate immunosuppression is not associated with early toxicity, risk of acute graft-versus-host disease or relapse following hematopoietic transplantation. Bone Marrow Transpl. 37 (2006), 687–692.
123. [123] Neurath, M., Hildner, K., Becker, C., et al. Methotrexate specifically modulates cytokine production by T cells and macrophages in murine collagen-induced arthritis (CIA): a mechanism for methotrexate-mediated immunosuppression. Clin. Exp. Immunol. 115 (1999), 42–55.
124. [124] Furst, D., The rational use of methotrexate in rheumatoid arthritis and other rheumatic diseases. Br. J. Rheumatol. 36 (1997), 1196–1204.
125. [125] Serra, J.M., Gutiérrez, A., Alemany, R., Navarro, M., Ros, T., Saus, C., et al. Inhibition of c-myc down-regulation by sustained extracellular signal-regulated kinase activation prevents the antimetabolite methtrexate- and gemcitabine-induced differentiation in non-small-cell lung cancer cells. Mol. Pharmacol. 73 (2008), 1679–1687.
126. [126] Thornton, C., Al-Rashed, F., Calay, D., Birdsey, G., Bauer, A., Mylroie, H., et al. Methotrexate-mediated activation of an AMPK-CREC-dependent pathway: a novel mechanism for vascular protection in chronic systemic inflammation. Ann. Rheum. Dis., 2015, 1–10.
127. [127] Pirkmajer, S., Kulkarni, S.S., Tom, R.Z., Ross, F.A., Hawley, S.A., Hardie, D.G., et al. Methotrexate promotes glucose uptake and lipid oxidation in skeletal muscle via AMPK activation. Diabetes, 64(360–369), 2015.
128. [128] Ho, P.-C., Bihuniak, J.D., Macintyre, A.N., Staron, M., Liu, X., Amezquita, R., et al. Phosphoenolpyruvate is a metabolic checkpoint of anti-tumor T cell responses. Cell. 162 (2015), 1217–1228.
129. [129] Wang, Y., Wang, X.-Y., Subjeck, J., Shrikant, P., Kim, H., Temsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccines. Br. J. Cancer 104 (2011), 643–652.
130. [130] Chaoul, N., Fayolle, C., Desrues, B., Oberkampf, M., Tang, A., Ladant, D., et al. Rapamycin impairs antitumor CD8+ T-cell responses and vaccine-induced tumor eradication. Cancer Res. 75:16 (2015), 3279–3291.
131. [131] Chang, C.-H., Pearce, E.L., Emerging concepts of T cell metabolism as a target of immunotherapy. Nat. Immunol. 17:4 (2016), 364–368.